Article Text

Download PDFPDF
Reply to ‘Are the 5-hydroxymethylcytosine-based wd-scores really superior over α-fetoprotein for the early diagnosis of hepatocellular carcinoma?’

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • CH, WZ and JF are joint senior authors.

  • JC and ZZ contributed equally.

  • Contributors All authors contributed significantly to the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests The 5-hydroxymethylcytosine-Seal (5hmC-Seal) technology was invented by CH and was licensed by Shanghai Epican Genetech Co. Ltd. for clinical applications in human diseases from the University of Chicago. CH and WZ are shareholders of Shanghai Epican Genetech Co. Ltd. CH is a scientific founder of Accent Therapeutics, Inc., and a member of its scientific advisory board.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.